Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Sudor is a purpose-built platform for fitness professionals and their clients. The company claims to provide the technology and tools to empower fitness professionals as they build their digital business. Its core vision is to disrupt YouTube's fitness section that isn't purpose-built for fitness, doesn’t support challenges, track progress, or allows for 1:1 classes etc. Sudor asserts that its platform is different. It allows trainers to earn from their first subscriber. Trainers can also upload on-demand videos, stream live classes or create challenges for their subscribers. Sudor stresses that this gives its business ultimate scalability. It aspires to dominate the digital fitness industry in the US that is set to be worth $15 billion by 2026. The company has raised £465,000 to date, won the NOAH London Startup of the Year, and signed over 200 trainers. The portal hosts over 20,000 users and has paid out over £160,000 to trainers. The company states it will use the investment to scale Sudor worldwide.
days to go:
Expired
investment:
£274,488
Sorbet is a proptech business which automates the processes of renting a house, aiming to streamline reporting, minimise the burden of administration and improve communication between agents, landlords, contractors and tenants.
days to go:
Expired
investment:
£239,341
Biohm is an eco-conscious bio-technology company that is revolutionising construction through nature-inspired innovation. The company has adopted methods such as circular construction system, biomimicry, and triagomy. Some of the company’s carbon-negative bio-based materials include building insulation made out of Mycelium (the root structure of mushrooms) and ORB (Organic Refuse Biocompound), a 100% natural sheet material made out of food and agricultural surplus. For its innovation, Biohm won the Waitrose and Partners Plan Plastic Prize: The Million Pound Challenge and a Power to Change grant worth £600,000 to build sustainable living premises. It has also been shortlisted as one of The United Nation’s ‘Young Champions of the Earth’. The company will use 38% of the investment to grow its team, 22% to scale Research and Development (R&D), 22% to protect its Intellectual Property (IP), and 18% for product accreditation.
days to go:
Expired
investment:
£790,700
Future You Cambridge is a company that sells clinically proven health supplements directly to consumers. Since its launch in 2016, it has sold products to over 100,000 customers. The company's Lactolycopene product received a patent in December 2017 and its Fertility+ product was also covered by the European Journal of Nutrition in a clinical paper and was shown to have resulted in a 40% increase in male fertility. The company's offerings now stand at 24 products, including the popular CBD product and its first product for pets, Curcupet-K9. Additionally, the company won the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year Awards and has 5-star ratings on Trustpilot. They will use the investment to scale up direct advertising campaigns, expand its product range by more than 10 new products, and invest in their website to make it more intuitive.
days to go:
Expired
investment:
£655,011
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
Improving the railway construction industry by collecting data to reduce inefficiencies and overspending. Rail Diary is a B2B SaaS product that is designed to analyse information on infrastructure projects to improve particular elements that plague the industry. These include the delivery, commercialisation and the health and safety of projects.
Rail Diary allows developers to monitor ongoing costs, forecast for the future and reduce the number of claims made. Rail Diary will generate revenue via a monthly subscription model ranging from £45 to £150, plus project fees.
days to go:
Expired
investment:
£50,544
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
